Ebpay生命医药出版社

Ebpay生命

102677

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.4 Breast Cancer (Dove Med Press)
  • 3.2 Clin Epidemiol
  • 2.6 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.7 Clin Interv Aging
  • 5.1 Drug Des Dev Ther
  • 3.1 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.6 Int J Women's Health
  • 2.9 Neuropsych Dis Treat
  • 2.8 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.2 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 3.0 Diabet Metab Synd Ob
  • 3.2 Psychol Res Behav Ma
  • 3.4 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.0 Risk Manag Healthc Policy
  • 4.1 J Inflamm Res
  • 2.0 Int J Gen Med
  • 3.4 J Hepatocell Carcinoma
  • 3.0 J Asthma Allergy
  • 2.2 Clin Cosmet Investig Dermatol
  • 2.4 J Multidiscip Healthc



更多详情 >>





已发表论文

DRD2 和 COMT 基因多态性与下丘脑 - 垂体 - 甲状腺轴和下丘脑 - 垂体 - 性腺轴功能以及抗精神病药物所致高催乳素血症和巨催乳素血症之间的相关性

 

Authors Wang Z, Li J, Chen H, Jin H, Wang S, Hu X

Received 30 January 2025

Accepted for publication 3 May 2025

Published 8 May 2025 Volume 2025:21 Pages 1011—1017

DOI http://doi.org/10.2147/NDT.S518275

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Taro Kishi

Zhenhua Wang,1 Jing Li,2 Haizhi Chen,1 Haiying Jin,1 Shiliang Wang,1 Xuqiang Hu1 

1Department of Psychiatry, Huzhou Third Municipal Hospital, the Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Center for Disease Control and Prevention, Huzhou City, Zhejiang, People’s Republic of China

Correspondence: Xuqiang Hu, Department of psychiatry, Huzhou Third Municipal Hospital, the Affiliated Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China, Email huxuqiang@hz3rd-hosp.cn

Purpose: This study aimed to investigate the relationship between dopamine receptor D2 (DRD2) and catechol-o-methyltransferase (COMT) gene polymorphism, hypothalamic-pituitary-thyroid (HPT) and hypothalamic-pituitary-gonadal (HPG) axes functions, and macroprolactinemia induced by antipsychotics.
Patients and Methods: A total of 133 patients with schizophrenia were selected and given risperidone (4~6mg/d) monotherapy. The polymorphisms of DRD2 Taq1A and COMT Val158Met were analyzed using RFLP-PCR at baseline, and the levels of total prolactin (T-PRL), macroprolactin, C peptide (C-P), estradiol (E2), cholesterol (TC), low density lipoprotein (LDL), insulin, cortisol, thyroid function, and reproductive hormone were measured at baseline and the end of the fourth week of treatment. The patients were divided into a hyperprolactinemia group and a macroprolactinemia group according to their levels of T-PRL and macroprolactin, and the differences in the above indexes between the two groups were analyzed.
Results: There was no significant difference in the DRD2 Taq1A or COMT Val158Met gene polymorphisms between the two groups. However, after four weeks of treatment, significant differences were observed between the two groups in terms of C-P (t= 2.16, p=0.04), E2 (t=− 3.89, p< 0.001), TC (t= − 2.54, p=0.01), insulin (t=− 3.93, p< 0.001), T3 (t= 2.31, p= 0.02), and FT3 (t=2.05, p=0.04).
Conclusion: DRD2 Taq1A and COMT Val158Met gene polymorphisms may not be effective in predicting macroprolactinemia, but changes in C-P, E2, TC, insulin, T3 and FT3 levels may have some suggestive significance for the differentiation of hyperprolactinemia and macroprolactinemia.

Keywords: prolactin, macroprolactin, hyperprolactinemia, schizophrenia, gene polymorphism

Download Article[PDF]